Document is current
Any future updates will be listed below
-
Authors
Humphrey, Toby J. L.
Qian, Wendi
Chen-Xu, Michael
Dowling, Francis
Gatley, Katrina
Adhikari, Rakshya
Hensman, Tracey
Stockley, Louise
Bassi, Abhinav
Bathla, Nikita
Dasgupta, Indranil
Dosanjh, Davinder P. S.
Jellingsø, Mads
Sørensen, Per
Jensen, Morten Lind
Callesen, Anne Weibel
Bradley, John R.
Jha, Vivekanand
Sommer, Morten O. A.
Hiemstra, Thomas F.
Smith, Rona M.
,
Alchi, Bassam
Alejmi, Abdulfattah
Basu, Neil
Bebb, Charlotte
Bell, Samira
Bhargava, Anudita
Bhandari, Sunil
Bingham, Coralie
Bramham, Kate
Caskey, Fergus
Chand, Sourabh
Chaudhry, Dhruva
Chaudhury, Arpita Ray
Chennamsetty, Sashidhar
Chitalia, Nihil
Chowdhury, Paramit
Curran, Simon
Davies, Simon
Davison, Rachel
Delaney, Michael
Dey, Vishal
Dick, Jonathan
Eid, Mahmoud
El-Damanawi, Ragada
Fluck, Sarah
Gama, Rouvick
Goldsmith, Christopher
Gkrania-Klotsas, Effrossyni
Griffin, Sian
Hull, Richard
Ignatius, Avinash
Jayne, David
Jones, Colin
Kamalnathan, Manivarma
Kolhe, Nitin
Lafont, Tanguy
Lambie, Mark
Lawman, Sarah
Ledson, Thomas
Lightstone, Liz
Lucas, Bethany
Mahalingasivam, Viyaasan
Mark, Patrick
McAdoo, Stephen
McCafferty, Kieran
Patrick, Jean
Prasad, Narayan
Pritchard, Nicholas
Rainone, Francesco
Ramachandran, Raja
Rathore, Vinay
Sahay, Manisha
Salama, Alan
Saxena, Sanjiv
Shah, Sapna
Sharpe, Claire
Spencer, Sebastian
Taylor, Jo
Trotter, Patrick
Udayaraj, Udaya
Ugni, Shiva
Wade, Josh
Wahba, Mona
Wason, James
Wilkie, Martin
Wilkinson, Ian
- License Information
-
More Information
Article History
Received: 18 March 2024
Accepted: 31 January 2025
First Online: 11 February 2025
Declarations
:
: The protocol was approved by the UK Medicines and Healthcare Products Regulatory Agency, South Central Berkshire Research Ethics Committee (REC Reference 20/SC/0403) in the UK and the Central Drugs Standard Control Organisation, India and the Ethics Committees of all participating sites in India.
: Not applicable.
: All authors have completed the Unified Competing Interest Form (available on request from the corresponding author) and declare the following: MCX has received PhD funding support from GlaxoSmithKline. ID has research grants from Sanofi, Baxter and NIHR CRN West Midlands; honoraria from GSK, Sanofi, Vifor and AstraZeneca; support to attend meetings from GlaxoSmithKline; and sits on DSMB/advisory boards for GlaxoSmithKline and Vifor. DD has received research grants from GlaxoSmithKline; sites on DSMB/advisory boards for Gilead Sciences Inc and Synairgen Plc and since May 2023 is an employee of AstraZeneca. MJ, PS and AWC are employees of Union therapeutics A/S. MLJ is an employee of Union therapeutics A/S and sits on the advisory board for Radiometer and board of directors for HEDIA. MAOS is a co-founder and shareholder at Union therapeutics A/S and a co-inventor on patents and patent applications around the use of niclosamide to treat COVID-19. VJ has received consulting fees from GlaxoSmithKline, Boehringer Ingelheim, Bayer, Vera, Visterra, Biocryst, AstraZeneca; honoraria from Baxter Healthcare and GlaxoSmithKline; and sits on DSMB/advisory boards for Zydus Lifesciences. TFH is and employee and shareholder at GlaxoSmithKline and is an ICH E20 working Group Member. RMS has received research grants from LifeArc, Kidney Research UK, Addenbrooke’s Charitable Trust, Union therapeutics A/S and GlaxoSmithKline for the PROTECT-V trial. TJLH, WQ, FD, RA, TH, LS, AB, NB, JRB have no conflicts of interest to declare.
